Dr Albert Oriol speaks to ecancer about a randomised phase 2 study which was presented at ASH 2020 regarding weekly carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple myeloma (MM) patients (GEM-KyCyDex).
He initially talks about the aims and objectives of the study saying that carfilzomib given twice a week in combination with dexamethasone (Kd) is a standard of care for RRMM after 1-3 prior lines.
On the other side, Cyclophosphamide is an alkylating agent that has been widely combined with proteasome inhibitors and immunomodulatory drugs in MM, improving their efficacy with a good safety profile.
He says that in this phase 2 randomised study, we have compared Kd plus cyclophosphamide (KCyd) with Kd in RRMM after 1-3PL, both with K dosed weekly at 70 mg/m2. Dr Oriol then talks about the key results from this study and how they can impact the future treatment of refractory multiple myeloma.
He winds the interview up by giving additional information on the subject and his opinion on how the research on this topic can proceed further.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.